Clinical Observation Of Arsenic Trioxide Combined With Intraperitoneal Hyperthermic Perfusion Chemotherapy In The Treatment Of Gastric Cancer Ascites

Object : This study observed the therapeutic effect of Arsenic Trioxide on patients with gastric cancer ascites,by observing the change of ascites Karnofsky(KPS),the volume of ascites,the change of tumor marker CEA,the changes of liver and kidney function,the changes of ECG,we can evaluate it’s clinical efficacy and safety,thus we can use it guiding the practice of clinical.Methods : 48 gastric cancer patients with ascites were randomly divided into the treatment group and the control group.The treatment group was treated with arsenic trioxide on hyperthermic perfusion chemotherapy combined with systemic chemotherapy,while the control group was given paclitaxel plus cisplatin intraperitoneal hyperthermic perfusion chemotherapy combined with paclitaxel intravenous systemic chemotherapy.Separate measurement the change of ascites KPS,the volume of ascites,the change of tumor marker CEA,the changes of liver and kidney function,the changes of ECG at before treatment,in therapy and after treatment,so we can comprehensive evaluation of their efficacy of the deffent group.Result : 1.KPS: Comparison within the same group: Compared the KPS on the treatment group: There was significant difference before and after treatment(P<0.05);Compared the KPS on the control group: There was significant difference before and after treatment(P<0.05).Comparison between the two groups: Comparison the KPS between the two groups before treatment: There was no significant difference between the two groups(P > 0.05);Comparison the KPS between the two groups after treatment: The treatment group was significantly better than the control group(P<0.05).2.Comparison of ascites: Comparison within the same group:Compared the ascites on the treatment group: There was significant difference before and after treatment(P<0.05);Compared the ascites on the control group: There was significant difference before and after treatment(P<0.05).Comparison between the two groups: Comparison the ascites between the two groups before treatment: There was no significant difference between the two groups(P > 0.05);Comparison the ascites between the two groups after treatment: The treatment group was significantly better than the control group(P<0.05).3.Comparison of CEA : Comparison within the same group: Compared the CEA on the treatment group: There was significant difference before and after treatment(P<0.05);Compared the CEA on the control group: There was significant difference before and after treatment(P<0.05).Comparison between the two groups:Comparison the CEA between the two groups before treatment: There was no significant difference between the two groups(P > 0.05);Comparison the CEA between the two groups after treatment: The two groups of similar efficacy(P >0.05).4.There was no significant difference between the two groups before and after treatment.Conclusion:Arsenic trioxide on hyperthermic perfusion chemotherapy combined with systemic chemotherapy can improve the patient’s physical condition,decreased serum CEA concentration,control ascites formation,relieve clinical symptoms,and improve the quality of life.It deserves further study.